Factors Influencing Time From Diagnosis to Treatment of Breast Cancer and the Impact of Longer Waiting Time on Survival in Kathmandu Valley, Nepal: A Population-Based Study.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
Aug 2024
Historique:
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: ppublish

Résumé

Longer time between breast cancer (BC) diagnosis and treatment initiation is associated with poorer survival, and this may be a factor behind disparities in global survival rates. We assessed time to BC treatment in the Kathmandu Valley, Nepal, including factors associated with longer waiting times and their impact on survival. We conducted a retrospective population-based study of BC cases recorded in the Kathmandu Valley Population-Based Cancer Registry between 2018 and 2019. Fieldwork survey through telephone was undertaken to collect additional sociodemographic and clinical information. Logistic regression was performed to identify factors associated with longer time to treatment, and Kaplan-Meier and Cox proportional hazard regression was used to examine survival time and evaluate the association between longer time to treatment and survival. Among the 385 patients with BC, one third waited >4 weeks from diagnosis to initial treatment. Lower education was associated with longer time to treatment (adjusted odds ratio, 1.63 [95% CI, 1.03 to 2.60]). The overall 3-year survival rate was 88.6% and survival was not associated with time to treatment ( In the Kathmandu Valley, Nepal, women with a lower education tend to wait longer from BC diagnosis to treatment. Patients with advanced-stage BC had poorer survival, and longer waiting time may be associated with poorer survival for women diagnosed with advanced-stage disease.

Identifiants

pubmed: 39088778
doi: 10.1200/GO.24.00095
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2400095

Auteurs

Ranjeeta Subedi (R)

School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
The Daffodil Centre, University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.

Nehmat Houssami (N)

School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
The Daffodil Centre, University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.

Carolyn Nickson (C)

The Daffodil Centre, University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.
Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.

Meghnath Dhimal (M)

Nepal Health Research Council, Government of Nepal, Kathmandu, Nepal.

Michael David (M)

The Daffodil Centre, University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.
School of Medicine and Dentistry, Griffith University, Gold Coast, Australia.

Xue Qin Yu (XQ)

School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
The Daffodil Centre, University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH